Home Alzheimer’s Disease Study Suggests Implementing New Evidence-Based Interventions Improves CRC Screening Rates

Study Suggests Implementing New Evidence-Based Interventions Improves CRC Screening Rates

According to a study of the Colorectal Cancer Control Program (CRCCP) published in Cancer, implementing new evidence-based interventions (EBIs) or enhancing those that already exist improves colorectal cancer (CRC) screening rates.

In addition, the results demonstrated that clinics with lower screening rates in the prior year experienced greater rate increases and may have benefited more from the use of CRCCP.

Importantly, the successful implementation of EBIs in primary care clinics remains dependent on other activities such as quality improvement initiatives, effective electronic health systems, and efficient referral and patient tracking systems for colonoscopy. However, these results demonstrate that introducing such evidence-based interventions as those identified in the current study can increase CRC screening rates in clinics.

“The results might be useful to other public health…

Continue Reading to the Source


Please enter your comment!
Please enter your name here

Most Popular

Toni Choueiri, MD, on What Multidisciplinary Stakeholders Should Know About CheckMate 9ER

Results from the phase 3 CheckMate 9ER trial (NCT03141177) presented at the American Society of Clinical Oncology (ASCO) 2021 Genitourinary Cancer Symposium revealed that...

Robert J. Motzer, MD, on the Rationale for the Phase 3 CheckMate 9ER Trial in Advanced RCC

Compared with sunitinib (Sutent), combination treatment with nivolumab and cabozantinib demonstrated improved efficacy and prolonged survival among patients with previously treated advanced renal cell...

PHERGain II Trial Launched to Examine Chemotherapy-Free Treatment for Patients With HER2+ Breast Cancer

A clinical trial to support the use of a chemotherapy-free therapeutic approach has been launched and will aim to demonstrate that this approach is...

FDA Grants Breakthrough Therapy Designation to Tipifarnib for Treatment of HRAS-Mutant HNSCC

The FDA has granted breakthrough therapy designation to the investigational drug tipifarnib for the treatment of patients with recurrent or metastatic HRAS-mutant head and...

Recent Comments